Chandra Vargeese - 05 Feb 2026 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Reporting relationship: Chief Technology Officer, Head of Platform Discovery Sciences
Issuer ticker: WVE
Reported as of: 05 Feb 2026
Net transaction value: -$43,417
SEC form: 4
Accepted by SEC: 11 Feb 2026, 21:00:05 UTC
Prior SEC filing: 05 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Chandra Vargeese

Key filing fact

Chandra Vargeese filed Form 4 for Wave Life Sciences Ltd. (WVE) on 11 Feb 2026.

Key facts

This page summarizes Chandra Vargeese's Form 4 filing for Wave Life Sciences Ltd. (WVE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 21:00.

Change

Previous filing in this sequence was filed on 05 Mar 2025.
Current net transaction value: -$43,417.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001657675 Primary reporting owner

Vargeese Chandra

Relationship: Chief Technology Officer, Head of Platform Discovery Sciences
Address: C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Chandra Vargeese
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +45,625
Change %: +12%
Price: $0.000000
Shares after: 411,474
Date: 05 Feb 2026
Ownership: Direct
Footnotes: F1, F2

WVE transaction

Ordinary Shares

Sale

Transaction value: $43,417
Shares: -3,228
Change %: -0.78%
Price: $13.45
Shares after: 408,246
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE transaction Derivative

Share Option (right to buy)

Award

Transaction value: $0
Shares: +273,750
Change %
Price: $0.000000
Shares after: 273,750
Date: 05 Feb 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 273,750
Exercise price: $12.75
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

Footnote F2

Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.

Footnote F3

On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

Footnote F4

The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

SEC remarks

Chief Technology Officer, Head of Platform Discovery Sciences